Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 3/20 | 0.53 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7259014 | 0.86 | BRD4 (0.46) | GABBR2GABBR1CYP2C9LMNACYP2D6 | |
| SCHEMBL17772922 | 0.84 | ALDH1A1 (0.45) | CYP2C9LMNACYP2D6CYP2C19CYP3A4 | |
| SCHEMBL16689325 | 0.83 | CHRNB2 (0.54) | GABBR2GABBR1CYP2C19MEN1KMT2A | |
| SCHEMBL5698049 | 0.83 | CHRNB2 (0.54) | GABBR2GABBR1CYP2C19MEN1KMT2A | |
| SCHEMBL16680615 | 0.82 | FFAR1 (0.49) | LMNAMEN1KMT2ATSHRFFAR1 | |
| SCHEMBL9613763 | 0.82 | FFAR1 (0.49) | LMNAMEN1KMT2ATSHRFFAR1 | |
| Hydrochloric Acid SCHEMBL9995401 | 0.81 | CHRNB2 (0.53) | GABBR2GABBR1CYP2C19MEN1KMT2A | |
| SCHEMBL28443405 | 0.79 | GABBR2 (0.46) | GABBR2GABBR1CYP2C9LMNACYP2D6 | |
| SCHEMBL30858708 | 0.78 | GABBR2 (0.42) | GABBR2GABBR1CYP2C9LMNACYP2D6 | |
| SCHEMBL6953158 | 0.77 | HSD17B10 (0.44) | GABBR2GABBR1CYP2C9LMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9044443-B2 | Methods of treating autism | CLINICAL RESEARCH ASSOCIATES, LLC (US) | 2015-06-02 | — | — | US | disclosed |
| US-20130261186-A1 | Methods of Treating Autism | SEASIDE THERAPEUTICS, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130012586-A1 | Methods of Treating Fragile X Syndrome | SEASIDE THERAPEUTICS, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012587-A1 | Methods of Treating Autism | SEASIDE THERAPEUTICS, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8278276-B2 | Methods of treating autism | SEASIDE THERAPEUTICS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8273715-B2 | Methods of treating fragile X syndrome | SEASIDE THERAPEUTICS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-20120129940-A1 | METHODS OF TREATING AUTISM | SEASIDE THERAPEUTICS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120122986-A1 | Methods of Treating Fragile X Syndrome | SEASIDE THERAPEUTICS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012586-A1 | Methods of Treating Fragile X Syndrome | GABRB1, GABBR1, GABBR2 | GABBR2 3/4885GABBR1 2/4885CYP2C9 3563/4885 |
| US-20120129940-A1 | METHODS OF TREATING AUTISM | GABRB3, GABRB2, GABBR1 | GABBR2 5/4885GABBR1 3/4885CYP2C9 4375/4885 |
| US-20120122986-A1 | Methods of Treating Fragile X Syndrome | GABRB1, GABBR1, GABBR2 | GABBR2 3/4885GABBR1 2/4885CYP2C9 3563/4885 |
| US-20130012587-A1 | Methods of Treating Autism | GABRB3, GABRB2, GABBR1 | GABBR2 5/4885GABBR1 3/4885CYP2C9 4375/4885 |
| US-20130261186-A1 | Methods of Treating Autism | GABRB2, GABRB3, GABRB1 | GABBR2 5/4885GABBR1 4/4885CYP2C9 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.